Neoadjuvant selpercatinib for advanced medullary thyroid cancer

BACKGROUND: Targeted kinase inhibitors have been increasingly utilized in the treatment of advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next generation selective RET inhibitors have been clinically validated, and selpercatinib was recently Food and Drug Admin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jozaghi, Yelda, Zafereo, Mark, Williams, Michelle D., Gule‐Monroe, Maria K., Wang, Jennifer, Grubbs, Elizabeth G., Vaporciyan, Ara, Hu, Mimi I., Busaidy, Naifa, Dadu, Ramona, Waguespack, Steven G., Subbiah, Vivek, Cabanillas, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756223/
https://www.ncbi.nlm.nih.gov/pubmed/33169506
http://dx.doi.org/10.1002/hed.26527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756223/
https://www.ncbi.nlm.nih.gov/pubmed/33169506
http://dx.doi.org/10.1002/hed.26527

Ejemplares similares